Tag: dostarlimab
-
Media Monitor: TIME Health Reports FDA-Approved Rectal Cancer Drug, Dementia Projections
TIME Health reports on dostarlimab, a newly FDA-approved immunotherapy for a mutation-linked rectal cancer, and a JAMA Neurology study projecting dementia cases could more than double by 2050.
HealthScience & TechnologyMedical SciencePolitics and GovernmentFederal Government dostarlimabrectal cancerimmunotherapydementiaJAMA Neurologycolor walkorgan transplantTIME Health